Please type a plus sign (+) inside this box [] Apprused through 09/30/2000. OMB 0651-003	+   31 Patent and Tradem	ark Office: U.S. DEPART	MENT OF C	PTO/SB/21 (6-99) OMMERCE			
Under the Paperwork Reduction Act of 1995, no person	ns are required to resp	Application Num		09/903,640			
UL 2 3 2004 TRANSMITTA	Filing Date		July 11, 2001				
FORM	First Named Inve	ntor	Avi Ashkenazi, et al.				
(to be used for all correspondence after	Group/Art Unit		1636				
	Examiner Name		Konstantina T. KATCHEVES				
Total Number of Pages in This Submission	308 pgs.	Attorney Docket N	lumber	39780-1618P2C48			
ENCLOSURES (check all that apply)							
Fee Transmittal Form Fee Attached Drawin Amendment / Response After Final Version with Markings Showing Changes Affidavits/declaration(s) Extension of Time Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Assignt for an A  Partition Provisi Provisi Provisi Termin Small I Request Remarks AUTHORIZA		nent Papers pplication) g(s) ng-related Papers Routing Slip (PTO/SB/69) companying Petition to Convert to a onal Application of Attorney, Revocation of Correspondence Address al Disclaimer chtity Statement t for Refund		After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information  Status Letter Additional Enclosure(s) (please identify below):  stamped return postcard; PTO Form 1449; copies of 9 cited reference			
1.52 or 1.53 SIGNA	1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY OR AGENT						
Firm Daphne Reddy, Reg. No. 53,507  or Individual name HELLER EHRMAN WHITE & McAULIFFE LLP							
Signature Saphue Re	Signature Saphue Reddy						
Date July 23, 2004	0	Customer Numb	er: 091	157/35489			
CERTIFICATE OF MAILING							
I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this date: July 23, 2004.							
Typed or printed name Sandra Puljic							
Signature Smarr	Pulsyic Date		Date	July 23, 2004			

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop \_\_; Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

OIPE COLLEGE

07.24.04

4/1434

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this date: July 23, 2004

[Express Mail Label EL 993 692 204 US]

Typed or printed name Sandra Puljic

Signature Date July 23, 2004

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Avi Ashkenazi, et al.

Docket No.:

39780-1618P2C48

Serial No.:

09/903,640

Group Art Unit:

1636

Filing Date:

July 11, 2001

Examiner:

Konstantina T. KATCHEVES

For:

SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS

**ENCODING THE SAME** 

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Mail Stop: Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on an attached Form PTO-1449 is information known to applicant(s). Each reference listed has been cited in a related patent application, US Serial No. 09/903,925 (claiming PRO 343 antibody); Our Ref. No. 39780-1618P2C49 and/or US Serial No. 09/909,320 (claiming PRO 343 nucleic acid); Our Ref. No. 39780-1618P2C80. A copy of each reference is provided herewith. Applicants submit these documents to ensure that all references are of record and considered in all related applications. Applicants respectfully request the Examiner to acknowledge consideration of the currently submitted references by initialing and returning form PTO-1449 in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.



	This sta	is statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):					
		(1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)  OR					
		(2) It is being filed within 3 months of entry of a national stage OR					
		(3) It is being filed before the mail date of the first Office Action on the merits OR					
		(4)		ing of a first Office Action after the filing of a ion under § 1.114.			
$\boxtimes$	37 C.F.R. $\S1.97(c)$ . If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in $\S1.491$ in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under $\S1.113$ or a notice of allowance under $\S1.311$ , then:						
		a certification as specified in §1.97(e) is provided below; or					
		a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.					
	37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a fit office action under §1.113 or a notice of allowance under §1.311, but before payment of the fee, then:						
	A.	a certification as specified in §1.97(e) is completed below; and					
	B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and						
	C. a fee of \$180.00 as set forth in \$1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.						
	Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$180.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. <u>08-1641 (Docket No. 39780-1618P2C48)</u> .						
				Respectfully submitted,			
Dated:	July 23,	2004		By: Rephre Reddy  Daphne Reddy  Reg. No. 53,507			

HELLER EHRMAN WHITE & MCAULIFFE LLP

Customer No. 09157/35489

275 Middlefield Road

Menlo Park, CA 94025-3506

Telephone: (650) 324-7000/Facsimile: (650) 324-0638

JUL 2 3 2004 3004

## AFTY. DOCKET NO.: **SERIAL NO.:** INFORMATION DISCLOSURE **STATEMENT** 09/903,640 39780-1618P2C48 APPLICANT: Avi Ashkenazi, et al. PTO-1449 FILING DATE: July 11, 2001 **GROUP: 1636 U.S. PATENT DOCUMENTS EXAMINER'S** PATENT NO. **CLASS SUBCLASS** DATE NAME FILING DATE **INITIALS** 5,821,337 10/13/1998 Carter, P., et al. 530 387.3 FOREIGN PATENT DOCUMENTS TRANSLATION **EXAMINER'S** PATENT NO. DATE **CLASS SUBCLASS** COUNTRY **INITIALS** YES NO WO 98/36054 8/20/1998 **PCT** C12N 9/12 $\Box$ OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Haynes, Paul A., et al., "Proteome analysis: Biological assay or data archive?", Electrophoresis, 19, 1998, pp 1862-1871 Konopka, James B., et al., "Variable expression of the translocated c-abl oncogene in Philadelphia-chromosome-positive Blymphoid cell lines from chronic myelogenous leukemia patients", Proc. Natl. Acad. Sci. USA, Vol 83, 1986, pp 4049-4052 Pennica, Diane, et al, "WISP genes are members of the connective tissue growth factor family that are up-regulated in Wnt-1-transformed cells and aberrantly expressed in human colon tumors", Proc. Natl. Acad. Sci. USA, Vol. 95, December 1998, pp 14717-14722 Accession No. AC003965, Direct Submission, Submitted: December 31, 1997, Ricke, D. O. et al. Accession No. AB010779, Direct Submission, Submitted: January 27, 1998, Yamaguchi et al. Accession No. AAA61698, WO 200031211-A1, Pub Date: June 2, 2000, Fuso Pharm. Ind. Ltd.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

**EXAMINER**